DYNT vs. QNRX, TNON, NMRD, INVO, AEMD, BJDX, IONM, STSS, AFIB, and UTRS
Should you be buying Dynatronics stock or one of its competitors? The main competitors of Dynatronics include Quoin Pharmaceuticals (QNRX), Tenon Medical (TNON), Nemaura Medical (NMRD), INVO Bioscience (INVO), Aethlon Medical (AEMD), Bluejay Diagnostics (BJDX), Assure (IONM), Sharps Technology (STSS), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "surgical & medical instruments" industry.
Quoin Pharmaceuticals (NASDAQ:QNRX) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
Quoin Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 532.81%. Dynatronics has a consensus target price of $3.80, indicating a potential upside of 544.29%. Given Quoin Pharmaceuticals' higher probable upside, analysts clearly believe Dynatronics is more favorable than Quoin Pharmaceuticals.
In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 1 articles in the media. Dynatronics' average media sentiment score of 0.67 beat Quoin Pharmaceuticals' score of 0.30 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.
Dynatronics has higher revenue and earnings than Quoin Pharmaceuticals. Dynatronics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Quoin Pharmaceuticals' net margin of -14.13%. Quoin Pharmaceuticals' return on equity of -54.88% beat Dynatronics' return on equity.
Quoin Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Dynatronics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 3.3% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 9.1% of Dynatronics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Dynatronics received 304 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 50.99% of users gave Dynatronics an outperform vote.
Summary
Quoin Pharmaceuticals and Dynatronics tied by winning 8 of the 16 factors compared between the two stocks.
Get Dynatronics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynatronics Competitors List
Related Companies and Tools
